Wang Zewei, Xie Huyang, Zhou Lin, Liu Zheng, Fu Hangcheng, Zhu Yu, Xu Le, Xu Jiejie
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Oncotarget. 2016 Aug 9;7(32):51525-51534. doi: 10.18632/oncotarget.10492.
Chemokine (C-Cmotif) ligand 2 (CCL2) is a major chemokine that recruit monocytes and macrophages to the sites of inflammation. Recent researches have clarified that overexpression of CCL2 is associated with unfavorable prognosis in various cancer types. In this study, we aim to determine the prognostic value of CCL2 expression as well as its receptor C-C motif receptor type 2 (CCR2) in patients with non-metastatic clear cell renal cell carcinoma (ccRCC) after surgery.
Both high CCL2 and CCR2 expression were remarkably correlated with shortened survival time (P < 0.001 and P < 0.001, respectively) and increased risk of recurrence (P = 0.001 and P = 0.003, respectively). The combination of CCL2 and CCR2 expression (CCL2/CCR2 signature) could offer a better prognostic stratification. Furthermore, multivariate analyses identified CCL2/CCR2 signature as an independent risk factor for overall survival (OS) and recurrence-free survival (RFS) (P = 0.007 and P = 0.043, respectively). The incorporation of CCL2/CCR2 signature would refine individual risk stratification and predictive accuracy of the well-established models.
We retrospectively examined the intratumoral expression of CCL2 and CCR2 by immunohistochemical staining in 268 histologically proven non-metastatic ccRCC patients receiving surgery in a single institution between 2001 and 2004. Kaplan-Meier analysis and Cox regression were applied to determine the prognostic value of CCL2 and CCR2 expression. Concordance index was calculated to compare predictive accuracy of the established models.
Combined CCL2 and CCR2 expression emerges as an independent prognostic factor for non-metastatic ccRCC patients after surgical treatment.
趋化因子（C-C基序）配体2（CCL2）是一种主要的趋化因子，可将单核细胞和巨噬细胞募集到炎症部位。最近的研究表明，CCL2的过表达与多种癌症类型的不良预后相关。在本研究中，我们旨在确定CCL2及其受体C-C基序受体2型（CCR2）在非转移性透明细胞肾细胞癌（ccRCC）患者术后的预后价值。
CCL2和CCR2的高表达均与生存时间缩短显著相关（分别为P < 0.001和P < 0.001）以及复发风险增加（分别为P = 0.001和P = 0.003）。CCL2和CCR2表达的联合（CCL2/CCR2特征）可提供更好的预后分层。此外，多变量分析确定CCL2/CCR2特征是总生存期（OS）和无复发生存期（RFS）的独立危险因素（分别为P = 0.007和P = 0.043）。纳入CCL2/CCR2特征将改善已建立模型的个体风险分层和预测准确性。
我们回顾性地通过免疫组织化学染色检查了2001年至2004年间在单个机构接受手术的268例经组织学证实的非转移性ccRCC患者肿瘤内CCL2和CCR2的表达。应用Kaplan-Meier分析和Cox回归来确定CCL2和CCR2表达的预后价值。计算一致性指数以比较已建立模型的预测准确性。
CCL2和CCR2的联合表达是手术治疗后非转移性ccRCC患者的独立预后因素。
